AtriCure, Inc just received an average of “buy” rating from ten stock market analysts. Out of the ten, one issued a rating of “sell”, one issued a rating of “hold” and eight issued a rating of “buy” to NASDAQ: ATRC. The company’s one year objective price is $52.71.
How Did The Stock Market Analysts React To NASDAQ: ATRC Report?
Piper Sandler increased its target price on AtriCure shares to $50 from $47. They also issued a rating of “overweight on 29th July during Wednesday’s report. BidaskClus also updated its NASDAQ: ATRCshares to a rating of “Buy” from a rating of “Hold” on 1st September during a Tuesday report. ValuEngine also increased its AtriCure shares to a rating of “buy” from a rating of “hold” on 3rd August during a Monday report.
JPMorgan Chase & Co increased their price target to $57.00 from $48.00 as well. They also issued a rating of “overweight” on 29th July during a Wednesday report. Last but not the least, Zacks Investment Research decreased AtriCure (NASDAQ: ATRC) shares to a rating of “hold” to a rating of “buy” on 29th September during a Tuesday report.
On Monday, AtriCure shares started at $0.10. NASDAQ: ATRC stock has a $1.86 billion market capitalization. Its price to earnings ratio and beta are -31.93 and 0.72. The firm also has $40.82 as its fifty days moving average and $42.10 as its two-hundred days moving average.
AtriCure Inc’s quick ratio, current ratio, and debt to equity ratio are 6.81, 7.67, and 0.16 respectively.
Which Investors Increased Or Decreased Their AtriCure Stocks Recently?
FMR LLC boosted its NASDAQ: ATRC position by 34.6 percent. They currently own an estimate of $214,268,000, which comes from 4,766,815 company shares.. Vanguard Group Inc also increased its ArtiCure stake by 10.9 percent. They currently own an estimate of $101,953,000, which comes from 2,268,168 company shares. Invesco Ltd also increased its NASDAQ: ATRC stakes by 348.9 percent. They currently own an estimate of $51,587,000, which comes from 1,535,792 company shares.
Fred Alger Management LLC recently acquired $42,438,000 worth of AtriCure Holdings for the first quarter. Last but not the least, Orbimed Advisors LLC increased its NASDAQ: ATRC stakes by 32.3 percent. They currently own an estimate of $55,207,900, which comes from 1,228,189 company shares.
It should be noted that 93.50 percent of AtriCure Inc (NASDAQ: ATRC) Stocks are owned by stock market investors and hedge funds.
On 28th July, AtriCure (NASDAQ: ATRC) revealed that the company’s quarterly earning is $0.38 EPS.
